share_log

HC Wainwright & Co. Maintains Buy on Purple Biotech, Adjusts Price Target To $33 (1-20 Reverse Stock Split)

Benzinga ·  Sep 20, 2024 10:38  · Ratings

HC Wainwright & Co. analyst Emily Bodnar maintains Purple Biotech (NASDAQ:PPBT) with a Buy, adjusts target to $33 from $8 (1-20 Reverse Stock Split).

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment